Evidence map›Paper›PMID 25473651›Full record

ArticleThe lancet. HIV2014

HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.

Jaimie P Meyer, Javier Cepeda, Sandra A Springer, Johnny Wu, Robert L Trestman, Frederick L Altice

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The lancet. HIV, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jaimie P MeyerSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).
Javier CepedaSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).
Sandra A SpringerSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).
Johnny WuSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).
Robert L TrestmanSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).
Frederick L AlticeSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).

Funding

Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI John Edward Pachankis · 2001 to 2026
$48.5M
INTERDISCIPLINARY HIV PREVENTION TRAINING PROGRAMT32MH020031 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 1999 to 2026
$12.1M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations TransitK02DA032322 · NIDA · YALE UNIVERSITY · PI SPRINGER, SANDRA ANN · 2011 to 2022
$1.3M
Evaluating and Improving HIV Outcomes in Community-Based Women who Interface withK23DA033858 · NIDA · YALE UNIVERSITY · PI MEYER, JAIMIE · 2012 to 2016
$821k
Characterizing the post-incarceration risk environment in St. Petersburg, RussiaF31DA035709 · NIDA · YALE UNIVERSITY · PI CEPEDA, JAVIER · 2013 to 2014
$81k
NIDA NIH HHS F31 DA035709NIDA NIH HHS K02 DA032322NIDA NIH HHS K23 DA033858NIDA NIH HHS K24 DA017072NIMH NIH HHS P30 MH062294NIMH NIH HHS T32 MH020031
6 · The paper itself

Abstract

backgroundReincarceration in prison or jail correlates with non-sustained HIV viral suppression, but HIV treatment outcomes in released prisoners who are reincarcerated have not recently been systematically assessed despite advances in antiretroviral treatment (ART) potency, simplicity, and tolerability.

methodsIn a retrospective cohort of reincarcerated inmates with HIV in Connecticut (2005-12), we used longitudinally linked demographic, pharmacy, and laboratory databases to examine correlates of viral suppression. The primary outcome was viral suppression on reincarceration, defined as viral load lower than 400 RNA copies per mL.

findingsOf 497 prisoners and jail detainees with HIV, with 934 reincarcerations, individuals were mostly unmarried, uninsured, and black men prescribed a protease-inhibitor-based ART regimen. During the median 329 days (IQR 179-621) between prison release and reincarceration, the proportion of incarceration periods with viral suppression decreased significantly from 52% to 31% (mean HIV-RNA increased by 0·4 log

interpretationIdentification of individuals most at risk for recidivism and loss of viral suppression might mitigate the risk that repeated reincarceration poses to systems of public health and safety.

fundingBristol-Myers Squibb Virology, Patterson Trust, and National Institute on Drug Abuse.

Identifiers

PMID25473651
PMCPMC4249702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.